Pfizer (PFE.US) PD-L1 ADC launched clinical trials for the first time in China

According to the Securities Times Financial News App, on May 12th, the drug clinical trial registration and information disclosure platform showed that Pfizer (PFE.US) has initiated a Phase I clinical trial for PF-08046054 targeting solid tumor patients in China. PF-08046054 (SGN-PDL1V) is a PD-L1-targeting ADC acquired by Pfizer from Seagen.